ZBH · Categories · Downgrades
ZBH - Analyst downgrades
Zimmer Biomet Holdings Inc. (ZBH) analyst downgrades - real-time wire coverage filtered to Downgrades only.
Recent Downgrades for ZBH
- Zimmer Biomet downgraded by BTIG ResearchBTIG Research downgraded Zimmer Biomet from Buy to Neutral
- Zimmer Biomet downgraded by Goldman with a new price targetGoldman downgraded Zimmer Biomet from Neutral to Sell and set a new price target of $93.00
- Zimmer Biomet downgraded by Raymond JamesRaymond James downgraded Zimmer Biomet from Outperform to Mkt Perform
- Zimmer Biomet downgraded by Robert W. Baird with a new price targetRobert W. Baird downgraded Zimmer Biomet from Outperform to Neutral and set a new price target of $100.00
- Zimmer Biomet downgraded by Analyst with a new price targetAnalyst downgraded Zimmer Biomet from Overweight to Neutral and set a new price target of $100.00
- Zimmer Biomet downgraded by Piper Sandler with a new price targetPiper Sandler downgraded Zimmer Biomet from Overweight to Neutral and set a new price target of $115.00 from $140.00 previously
- Zimmer Biomet downgraded by Evercore ISI with a new price targetEvercore ISI downgraded Zimmer Biomet from Outperform to In-line and set a new price target of $125.00 from $135.00 previously
- Zimmer Biomet downgraded by Evercore ISI with a new price targetEvercore ISI downgraded Zimmer Biomet from Outperform to In-line and set a new price target of $130.00
- Zimmer Biomet downgraded by NeedhamNeedham downgraded Zimmer Biomet from Buy to Hold
- Zimmer Biomet downgraded by Truist with a new price targetTruist downgraded Zimmer Biomet from Buy to Hold and set a new price target of $142.00 from $128.00 previously
- Zimmer Biomet downgraded by Citigroup with a new price targetCitigroup downgraded Zimmer Biomet from Buy to Neutral and set a new price target of $135.00 from $125.15 previously
- Zimmer Biomet Holdings downgraded by Loop Capital with a new price targetLoop Capital downgraded Zimmer Biomet Holdings from Buy to Hold and set a new price target of $130.00
- Zimmer Biomet Holdings downgraded by Canaccord Genuity with a new price targetCanaccord Genuity downgraded Zimmer Biomet Holdings from Buy to Hold and set a new price target of $125.00 from $165.00 previously
- Zimmer Biomet downgraded by UBS with a new price targetUBS downgraded Zimmer Biomet from Buy to Neutral and set a new price target of $130.00 from $172.00 previously
- Zimmer Biomet downgraded by Wells Fargo with a new price targetWells Fargo downgraded Zimmer Biomet from Overweight to Underweight and set a new price target of $124.00 from $170.00 previously
- Zimmer Biomet downgraded by MizuhoMizuho downgraded Zimmer Biomet from Buy to Neutral
- Zimmer Biomet Holdings downgraded by BTIGBTIG downgraded Zimmer Biomet Holdings from Buy to Neutral
- Zimmer Biomet Holdings downgraded by Morgan Stanley with a new price targetMorgan Stanley downgraded Zimmer Biomet Holdings from Overweight to Equal-Weight and set a new price target of $145.00 from $165.00 previously
- Zimmer Biomet Holdings downgraded by Piper Sandler with a new price targetPiper Sandler downgraded Zimmer Biomet Holdings from Overweight to Neutral and set a new price target of $135.00 from $185.00 previously
- Zimmer Biomet Holdings downgraded by Needham with a new price targetNeedham downgraded Zimmer Biomet Holdings from Strong Buy to Buy and set a new price target of $158.00 from $175.00 previously
- Zimmer Biomet Holdings downgraded by Argus ResearchArgus Research downgraded Zimmer Biomet Holdings from Buy to Hold